PI3K keeps the balance between metabolism and cancer

Advances in Biological Regulation

Volumn 52, Issue 3, 2012, Pages 389-405

  Braccini, L ^a   Ciraolo, E ^a   Martini, M ^a   Pirali, T ^b   Germena, G ^a   Rolfo, K ^c   Hirsch, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Istituto di Ricerche Biomediche Antoine Marxer SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864554955     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2012.04.002     Document Type: Review

References (147)

1. Aleksandrova K., Boeing H., Jenab M., Bas Bueno-de-Mesquita H., Jansen E., van Duijnhoven F.J., et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila) 2011, 4:1873-1883.
2. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., Nardella C., Egia A., et al. Subtle variations in PTEN dose determine cancer susceptibility. Nat Genet 2010, 42:454-458.
3. Arcaro A., Volinia S., Zvelebil M.J., Stein R., Watton S.J., Layton M.J., et al. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem 1998, 273:33082-33090.
4. Bader A.G., Kang S., Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 2006, 103:1475-1479.
5. Banfic H., Visnjic D., Mise N., Balakrishnan S., Deplano S., Korchev Y.E., et al. Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2beta to the nucleus. Biochem J 2009, 422:53-60.
6. Barnache S., Le Scolan E., Kosmider O., Denis N., Moreau-Gachelin F. Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene 2006, 25:1420-1423.
7. Barthel A., Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2003, 285:E685-E692.
8. Becattini B., Marone R., Zani F., Arsenijevic D., Seydoux J., Montani J.P., et al. PI3Kgamma within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc Natl Acad Sci U S A 2011, 108:E854-E863.
9. Call R., Grimsley M., Cadwallader L., Cialone L., Hill M., Hreish V., et al. Insulin - carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med 2010, 122:158-165.
10. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
11. Castillo J.J., Furman M., Winer E.S. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012, 21:15-22.
12. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
13. Chaussade C., Cho K., Mawson C., Rewcastle G.W., Shepherd P.R. Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem Biophys Res Commun 2009, 381:577-581.
14. Ciraolo E., Iezzi M., Marone R., Marengo S., Curcio C., Costa C., et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 2008, 1:ra3.
15. Clement S., Krause U., Desmedt F., Tanti J.F., Behrends J., Pesesse X., et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001, 409:92-97.
16. Crljen V., Volinia S., Banfic H. Hepatocyte growth factor activates phosphoinositide 3-kinase C2 beta in renal brush-border plasma membranes. Biochem J 2002, 365:791-799.
17. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
18. Daimon M., Sato H., Oizumi T., Toriyama S., Saito T., Karasawa S., et al. Association of the PIK3C2G gene polymorphisms with type 2 DM in a Japanese population. Biochem Biophys Res Commun 2008, 365:466-471.
19. Damen J.E., Liu L., Rosten P., Humphries R.K., Jefferson A.B., Majerus P.W., et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci U S A 1996, 93:1689-1693.
20. Didichenko S.A., Thelen M. Phosphatidylinositol 3-kinase C2alpha contains a nuclear localization sequence and associates with nuclear speckles. J Biol Chem 2001, 276:48135-48142.
21. Domin J., Gaidarov I., Smith M.E., Keen J.H., Waterfield M.D. The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. J Biol Chem 2000, 275:11943-11950.
22. Domin J., Pages F., Volinia S., Rittenhouse S.E., Zvelebil M.J., Stein R.C., et al. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor Wortmannin. Biochem J 1997, 326(Pt 1):139-147.
23. Dominguez V., Raimondi C., Somanath S., Bugliani M., Loder M.K., Edling C.E., et al. Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. J Biol Chem 2011, 286:4216-4225.
24. Edling C.E., Selvaggi F., Buus R., Maffucci T., Di Sebastiano P., Friess H., et al. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 2010, 16:4928-4937.
25. Elis W., Triantafellow E., Wolters N.M., Sian K.R., Caponigro G., Borawski J., et al. Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death. Mol Cancer Res 2008, 6:614-623.
26. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003, 22:183-198.
27. Falasca M., Maffucci T. Role of class II phosphoinositide 3-kinase in cell signalling. Biochem Soc Trans 2007, 35:211-214.
28. Falasca M., Maffucci T. Rethinking phosphatidylinositol 3-monophosphate. Biochim Biophys Acta 2009, 1793:1795-1803.
29. Farese R.V., Sajan M.P., Standaert M.L. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp Biol Med (Maywood) 2005, 230:593-605.
30. Farese R.V., Sajan M.P., Yang H., Li P., Mastorides S., Gower W.R., et al. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 2007, 117:2289-2301.
31. Fedele C.G., Ooms L.M., Ho M., Vieusseux J., O'Toole S.A., Millar E.K., et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A 2010, 107:22231-22236.
32. Fei G., Ebert M.P., Mawrin C., Leodolter A., Schmidt N., Dietzmann K., et al. Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives. Eur J Gastroenterol Hepatol 2002, 14:297-303.
33. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008, 51:5522-5532.
34. Fransson S., Uv A., Eriksson H., Andersson M.K., Wettergren Y., Bergo M., et al. p37delta is a new isoform of PI3K p110delta that increases cell proliferation and is overexpressed in tumors. Oncogene 2011.
35. Fukui K., Wada T., Kagawa S., Nagira K., Ikubo M., Ishihara H., et al. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2) on insulin signaling and glucose metabolism in mice. Diabetes 2005, 54:1958-1967.
36. Gallagher E.J., Fierz Y., Vijayakumar A., Haddad N., Yakar S., Leroith D. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 2011.
37. Garcia-Cao I., Song M.S., Hobbs R.M., Laurent G., Giorgi C., de Boer V.C., et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012.
38. Garlich J.R., De P., Dey N., Su J.D., Peng X., Miller A., et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008, 68:206-215.
39. Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
40. Gonzalez-Garcia A., Sanchez-Ruiz J., Flores J.M., Carrera A.C. Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer. Gastroenterology 2010, 138:1374-1383.
41. Guerreiro A.S., Fattet S., Kulesza D.W., Atamer A., Elsing A.N., Shalaby T., et al. A sensitized RNA interference screen identifies a novel role for the PI3K p110gamma isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res 2011, 9:925-935.
42. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008, 105:8292-8297.
43. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997, 57:3660-3663.
44. Gutierrez A., Sanda T., Grebliunaite R., Carracedo A., Salmena L., Ahn Y., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114:647-650.
45. Han S.Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000, 60:3147-3151.
46. Harada T., Chelala C., Bhakta V., Chaplin T., Caulee K., Baril P., et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2008, 27:1951-1960.
47. Heald B., Mester J., Rybicki L., Orloff M.S., Burke C.A., Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010, 139:1927-1933.
48. Hernandez-Sanchez C., Mansilla A., de la Rosa E.J., de Pablo F. Proinsulin in development: new roles for an ancient prohormone. Diabetologia 2006, 49:1142-1150.
49. Hirsch E., Costa C., Ciraolo E. Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. J Endocrinol 2007, 194:243-256.
50. Ho L.K., Liu D., Rozycka M., Brown R.A., Fry M.J. Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily. Biochem Biophys Res Commun 1997, 235:130-137.
51. Hoellenriegel J., Meadows S.A., Sivina M., Wierda W.G., Kantarjian H., Keating M.J., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612.
52. Huse J.T., Brennan C., Hambardzumyan D., Wee B., Pena J., Rouhanifard S.H., et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009, 23:1327-1337.
53. Ihle N.T., Williams R., Chow S., Chew W., Berggren M.I., Paine-Murrieta G., et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004, 3:763-772.
54. Ivetac I., Munday A.D., Kisseleva M.V., Zhang X.M., Luff S., Tiganis T., et al. The type Ialpha inositol polyphosphate 4-phosphatase generates and terminates phosphoinositide 3-kinase signals on endosomes and the plasma membrane. Mol Biol Cell 2005, 16:2218-2233.
55. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
56. Juhasz G., Hill J.H., Yan Y., Sass M., Baehrecke E.H., Backer J.M., et al. The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila. J Cell Biol 2008, 181:655-666.
57. Kalaany N.Y., Sabatini D.M. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009, 458:725-731.
58. Kang S., Denley A., Vanhaesebroeck B., Vogt P.K. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006, 103:1289-1294.
59. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125:733-747.
60. Kobayashi N., Ueki K., Okazaki Y., Iwane A., Kubota N., Ohsugi M., et al. Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proc Natl Acad Sci U S A 2011, 108:5753-5758.
61. Kong D.X., Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin 2010, 31:1189-1197.
62. Kroemer G., Marino G., Levine B. Autophagy and the integrated stress response. Mol Cell 2010, 40:280-293.
63. Kwon J., Lee S.R., Yang K.S., Ahn Y., Kim Y.J., Stadtman E.R., et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 2004, 101:16419-16424.
64. Lee C., Raffaghello L., Brandhorst S., Safdie F.M., Bianchi G., Martin-Montalvo A., et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 2012, 4:124ra27.
65. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99:323-334.
66. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
67. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
68. Li Y., Dowbenko D., Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002, 277:11352-11361.
69. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67.
70. Lin Y., Jiang X., Shen Y., Li M., Ma H., Xing M., et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 2009, 16:301-310.
71. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
72. Liu Q., Sasaki T., Kozieradzki I., Wakeham A., Itie A., Dumont D.J., et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev 1999, 13:786-791.
73. Lo T.C., Barnhill L.M., Kim Y., Nakae E.A., Yu A.L., Diccianni M.B. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk Res 2009, 33:1562-1566.
74. Locke N.R., Patterson S.J., Hamilton M.J., Sly L.M., Krystal G., Levings M.K. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J Immunol 2009, 183:975-983.
75. Luk S.K., Piekorz R.P., Nurnberg B., Tony To S.S. The catalytic phosphoinositol 3-kinase isoform p110delta is required for glioma cell migration and invasion. Eur J Cancer 2012, 48:149-157.
76. Luo J.M., Yoshida H., Komura S., Ohishi N., Pan L., Shigeno K., et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003, 17:1-8.
77. Ma K., Cheung S.M., Marshall A.J., Duronio V. PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/Akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal 2008, 20:684-694.
78. Ma Y.Y., Wei S.J., Lin Y.C., Lung J.C., Chang T.C., Whang-Peng J., et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000, 19:2739-2744.
79. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863.
80. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
81. Marino G., Kroemer G. Ammonia: a diffusible factor released by proliferating cells that induces autophagy. Sci Signal 2010, 3:pe19.
82. Martin D., Galisteo R., Molinolo A.A., Wetzker R., Hirsch E., Gutkind J.S. PI3Kgamma mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 2011, 19:805-813.
83. Matsumoto M., Ogawa W., Akimoto K., Inoue H., Miyake K., Furukawa K., et al. PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 2003, 112:935-944.
84. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001, 98:11598-11603.
85. Mazza S., Maffucci T. Class II phosphoinositide 3-kinase C2alpha: what we learned so far. Int J Biochem Mol Biol 2011, 2:168-182.
86. Medema R.H., Kops G.J., Bos J.L., Burgering B.M. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787.
87. Milazzo G., Giorgino F., Damante G., Sung C., Stampfer M.R., Vigneri R., et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992, 52:3924-3930.
88. Mirmohammadsadegh A., Marini A., Nambiar S., Hassan M., Tannapfel A., Ruzicka T., et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006, 66:6546-6552.
89. Morrow C.J., Gray A., Dive C. Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett 2005, 579:5123-5128.
90. Munday A.D., Norris F.A., Caldwell K.K., Brown S., Majerus P.W., Mitchell C.A. The inositol polyphosphate 4-phosphatase forms a complex with phosphatidylinositol 3-kinase in human platelet cytosol. Proc Natl Acad Sci U S A 1999, 96:3640-3645.
91. Murray D., Honig B. Electrostatic control of the membrane targeting of C2 domains. Mol Cell 2002, 9:145-154.
92. Naylor T.L., Greshock J., Wang Y., Colligon T., Yu Q.C., Clemmer V., et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005, 7:R1186-R1198.
93. Norris F.A., Majerus P.W. Hydrolysis of phosphatidylinositol 3,4-bisphosphate by inositol polyphosphate 4-phosphatase isolated by affinity elution chromatography. J Biol Chem 1994, 269:8716-8720.
94. Nystuen A., Legare M.E., Shultz L.D., Frankel W.N. A null mutation in inositol polyphosphate 4-phosphatase type I causes selective neuronal loss in weeble mutant mice. Neuron 2001, 32:203-212.
95. Odorizzi G., Babst M., Emr S.D. Phosphoinositide signaling and the regulation of membrane trafficking in yeast. Trends Biochem Sci 2000, 25:229-235.
96. Osaki M., Kase S., Adachi K., Takeda A., Hashimoto K., Ito H. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 2004, 130:8-14.
97. Pandini G., Vigneri R., Costantino A., Frasca F., Ippolito A., Fujita-Yamaguchi Y., et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999, 5:1935-1944.
98. Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990, 86:1503-1510.
99. Pedrero J.M., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodrigo J.P., Nieto C.S., et al. Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005, 114:242-248.
100. Prasad N.K., Tandon M., Handa A., Moore G.E., Babbs C.F., Snyder P.W., et al. High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumour Biol 2008, 29:330-341.
101. Rahdar M., Inoue T., Meyer T., Zhang J., Vazquez F., Devreotes P.N. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A 2009, 106:480-485.
102. Rosato V., Bosetti C., Talamini R., Levi F., Montella M., Giacosa A., et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011, 22:2687-2692.
103. Rosato V., Tavani A., Bosetti C., Pelucchi C., Talamini R., Polesel J., et al. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism 2011, 60:1372-1378.
104. Rozycka M., Lu Y.J., Brown R.A., Lau M.R., Shipley J.M., Fry M.J. cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics 1998, 54:569-574.
105. Rynkiewicz N.K., Liu H.J., Balamatsias D., Mitchell C.A. INPP4A/INPP4B and P-Rex proteins: related but different?. Adv Enzyme Regul 2011.
106. Saal L.H., Johansson P., Holm K., Gruvberger-Saal S.K., She Q.B., Maurer M., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007, 104:7564-7569.
107. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
108. Samuels Y., Diaz L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573.
109. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
110. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963.
111. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
112. Schmid M.C., Avraamides C.J., Dippold H.C., Franco I., Foubert P., Ellies L.G., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011, 19:715-727.
113. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008, 68:8022-8030.
114. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999, 21:99-102.
115. Shaywitz A.J., Courtney K.D., Patnaik A., Cantley L.C. PI3K enters beta-testing. Cell Metab 2008, 8:179-181.
116. Shearn C.T., Norris F.A. Biochemical characterization of the type I inositol polyphosphate 4-phosphatase C2 domain. Biochem Biophys Res Commun 2007, 356:255-259.
117. Shepherd P.R. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005, 183:3-12.
118. Shin S.H., Kim J.S., Kim H.R., Lim J.K., Choi B.K., Yeo Y.K. Polyphosphoinositides are derived from ether-linked inositol glycerophospholipids in rat brain. J Biochem Mol Biol 2005, 38:360-365.
119. Sleeman M.W., Wortley K.E., Lai K.M., Gowen L.C., Kintner J., Kline W.O., et al. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 2005, 11:199-205.
120. Spitzenberg V., Konig C., Ulm S., Marone R., Ropke L., Muller J.P., et al. Targeting PI3K in neuroblastoma. J Cancer Res Clin Oncol 2010, 136:1881-1890.
121. Sujobert P., Bardet V., Cornillet-Lefebvre P., Hayflick J.S., Prie N., Verdier F., et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106:1063-1066.
122. Sutherlin D.P., Bao L., Berry M., Castanedo G., Chuckowree I., Dotson J., et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 2011, 54:7579-7587.
123. Suwa A., Yamamoto T., Sawada A., Minoura K., Hosogai N., Tahara A., et al. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Br J Pharmacol 2009, 158:879-887.
124. Szanto A., Bognar Z., Szigeti A., Szabo A., Farkas L., Gallyas F. Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells. Anticancer Res 2009, 29:159-164.
125. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006, 7:85-96.
126. Taniguchi C.M., Kondo T., Sajan M., Luo J., Bronson R., Asano T., et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab 2006, 3:343-353.
127. Tay Y., Kats L., Salmena L., Weiss D., Tan S.M., Ala U., et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147:344-357.
128. Traer C.J., Foster F.M., Abraham S.M., Fry M.J. Are class II phosphoinositide 3-kinases potential targets for anticancer therapies?. Bull Cancer 2006, 93:E53-E58.
129. Trotman L.C., Wang X., Alimonti A., Chen Z., Teruya-Feldstein J., Yang H., et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128:141-156.
130. Tsuruta H., Kishimoto H., Sasaki T., Horie Y., Natsui M., Shibata Y., et al. Hyperplasia and carcinomas in PTEN-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006, 66:8389-8396.
131. Tu Z., Ninos J.M., Ma Z., Wang J.W., Lemos M.P., Desponts C., et al. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein. Blood 2001, 98:2028-2038.
132. Turner S.J., Domin J., Waterfield M.D., Ward S.G., Westwick J. The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. J Biol Chem 1998, 273:25987-25995.
133. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11:329-341.
134. Vanhaesebroeck B., Stephens L., Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012, 13:195-203.
135. Wang X., Proud C.G. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 2006, 21:362-369.
136. Wee S., Wiederschain D., Maira S.M., Loo A., Miller C., deBeaumont R., et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008, 105:13057-13062.
137. Welzel T.M., Graubard B.I., Zeuzem S., El-Serag H.B., Davila J.A., McGlynn K.A. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54:463-471.
138. Willems L., Tamburini J., Chapuis N., Lacombe C., Mayeux P., Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012, 14:129-138.
139. Wu Y., Brodt P., Sun H., Mejia W., Novosyadlyy R., Nunez N., et al. Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 2010, 70:57-67.
140. Wu Y., Cui K., Miyoshi K., Hennighausen L., Green J.E., Setser J., et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003, 63:4384-4388.
141. Wu Y., Yakar S., Zhao L., Hennighausen L., LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002, 62:1030-1035.
142. Yaguchi S., Izumisawa Y., Sato M., Nakagane T., Koshimizu I., Sakita K., et al. In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Biol Pharm Bull 1997, 20:698-700.
143. Zhang H., Fagan D.H., Zeng X., Freeman K.T., Sachdev D., Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010, 29:2517-2527.
144. Zhao J.J., Liu Z., Wang L., Shin E., Loda M.F., Roberts T.M. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 2005, 102:18443-18448.
145. Zhao L., Vogt P.K. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 2010, 9:596-600.
146. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 2007, 104:16158-16163.
147. Zippo A., De Robertis A., Bardelli M., Galvagni F., Oliviero S. Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 2004, 103:4536-4544.